HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Abstract
Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
AuthorsDik J Kwekkeboom, Wouter W de Herder, Eric P Krenning
JournalEndocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) Vol. 40 Issue 1 Pg. 173-85, ix (Mar 2011) ISSN: 1558-4410 [Electronic] United States
PMID21349418 (Publication Type: Evaluation Studies, Journal Article, Review)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Indium Radioisotopes
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • Lutetium
  • Octreotide
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Gastrointestinal Neoplasms (diagnosis, mortality, radionuclide imaging, radiotherapy)
  • Humans
  • Indium Radioisotopes (therapeutic use)
  • Lutetium (therapeutic use)
  • Molecular Targeted Therapy (methods)
  • Neuroendocrine Tumors (diagnosis, mortality, radionuclide imaging, radiotherapy)
  • Octreotide (analogs & derivatives, therapeutic use)
  • Pancreatic Neoplasms (diagnosis, mortality, radionuclide imaging, radiotherapy)
  • Radioisotopes (therapeutic use)
  • Radiopharmaceuticals (therapeutic use)
  • Receptors, Somatostatin (antagonists & inhibitors)
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: